



Supporting Information

for

Organocatalytic asymmetric nitroso aldol reaction of α -substituted malonamates

Ekta Gupta, Narendra Kumar Vaishnav, Sandeep Kumar, Raja Krishnan Purshottam, Ruchir Kant and Kishor Mohanan

Beilstein J. Org. Chem. **2022**, *18*, 217–224. doi:10.3762/bjoc.18.25

Detailed experimental procedures, complete characterization data for all compounds, single-crystal X-ray data of 4a, copies of NMR spectra, and HPLC chromatograms

Table of contents


1. General experimental information	S2
2. Characterization data for compounds 4a–y and 5	S3
3. X-ray data of compound 4a	S16
4. References	S17
5. Copies of ^1H and ^{13}C NMR spectra for all compounds	S18
6. HPLC Chromatograms of all compounds	S44

General experimental information:

Unless otherwise specified, all reactions were carried out under air atmosphere in oven-dried round-bottomed flasks. The reactions were monitored by TLC visualized by UV (254 nm) and/or with iodine. Flash chromatography was performed on 100–200 mesh silica gel using the gradient system ethyl acetate/hexane. NMR data were recorded with a Bruker AV 400 MHz spectrometer in CDCl_3 using as internal standards the residual CHCl_3 signal for ^1H NMR ($\delta = 7.26$ ppm) and the deuterated solvent signal for ^{13}C NMR ($\delta = 77.16$ ppm). Coupling constants are given in hertz (Hz) and the standard abbreviations are used to describe the signal multiplicities. Melting points were measured with a Büchi B-540 melting point apparatus and are uncorrected. High resolution mass spectra were obtained using a Q-TOF mass spectrometer. The ee values were determined on a Waters Standard HPLC System using chiral column with hexane and ethanol as eluent, wavelength = 254 nm. All commercially available reagents were used as received. α -Methylmalonamates **1a–u** were synthesized following a literature procedure.¹


Characterization data for compounds 4a–y and 5

(S)-Methyl 3-((4-bromophenyl)amino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxopropanoate (4a)




Following the general procedure, treatment of methyl 3-((4-bromophenyl)amino)-2-methyl-3-oxopropanoate (**1a**, 57 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4a** as white solid (71 mg, 90%). R_f (EtOAc/hexane 3:7) = 0.20. **Mp** 115–117 °C. ^{13}C NMR (100 MHz, δ ppm/CDCl₃): 171.5 (C), 167.0 (C), 147.1 (C), 136.5 (C), 132.1 (CH), 132.1(CH), 128.9 (CH), 128.9 (CH), 126.1 (CH), 122.2 (CH), 122.2 (CH), 121.6 (CH), 121.6 (CH), 117.4 (C), 76.8 (C), 53.5 (CH₃), 17.9 (CH₃). 1H NMR (400 MHz, δ ppm/CDCl₃): 9.04 (s, 1H), 7.47–7.44 (m, 5H), 7.31–7.26 (m, 2H), 7.20–7.14 (m, 3H), 3.81 (s, 3H), 1.59 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 13.0$ min, $\tau_{\text{major}} = 13.9$ min, 90% ee). HRMS for $C_{17}H_{17}BrN_2NaO_4^+$: calcd. [M+Na]⁺: 415.0264, found: 415.0278, [M+2+Na]⁺: 417.0257.

(S)-Methyl 2-(hydroxy(phenyl)amino)-2-methyl-3-(*p*-tolylamino)propanoate (4b)




Following the general procedure, treatment of methyl 2-methyl-3-oxo-3-(*p*-tolylamino)propanoate (**1b**, 44 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4b** as white solid (62 mg, 95%). R_f (EtOAc/hexane 3:7) = 0.28. **Mp** 149–151 °C. ^{13}C NMR (100 MHz, δ ppm/CDCl₃): 171.7 (C), 166.5 (C), 147.3 (C), 134.9 (C), 134.4 (C), 129.6 (CH), 129.6 (CH), 128.8 (CH), 125.7 (CH), 121.9 (CH), 121.9 (CH), 120.0 (CH), 120.0 (CH), 77.2 (C), 53.3 (CH₃), 20.9 (CH₃), 17.6 (CH₃). 1H NMR (400 MHz, δ ppm/CDCl₃): 9.00 (s, 1H), 7.48 (d, J = 8.4 Hz, 2H), 7.45 (s, 1H), 7.34–7.26 (m, 4H), 7.17 (d, J = 8.0, 3H), 3.85 (s, 3H), 2.36 (s, 3H), 1.65 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 28.9$ min, $\tau_{\text{major}} = 32.8$ min, 84% ee). HRMS for $C_{18}H_{20}N_2NaO_4^+$: calcd. [M+Na]⁺: 351.1315, found: 351.1323.

(S)-Methyl 3-((4-chlorophenyl)amino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxopropanoate (4c)




Following the general procedure, treatment of methyl 3-((4-chlorophenyl)amino)-2-methyl-3-oxopropanoate (**1c**, 48 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4c** as white solid (66 mg, 95%). R_f (EtOAc/hexane 3:7) = 0.5. **Mp** 134-136 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 171.6 (C), 167.0 (C), 147.1 (C), 136.0 (C), 129.8 (C), 129.2 (CH), 129.2 (CH), 129.0 (CH), 129.0 (CH), 126.1 (CH), 122.2 (CH), 122.2 (CH), 121.3 (CH), 121.3 (CH), 76.8 (C), 53.5 (CH₃), 18.1 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 9.03 (s, 1H), 7.51 (d, *J* = 8.8 Hz, 2H), 7.39 (s, 1H), 7.31-7.28 (m, 4H), 7.21-7.15 (m, 3H), 3.82 (s, 3H), 1.60 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 6.7$ min, $\tau_{\text{major}} = 7.2$ min, 83% ee). **HRMS** for C₁₇H₁₈ClN₂O₄⁺: calcd. [M+H]⁺: 349.0950, found: 349.0940, [M+2+H]⁺: 351.0910.

(S)-Methyl 3-((4-fluorophenyl)amino)-2-(hydroxy(phenyl)aminomethyl)-3-oxopropanoate (4d)




Following the general procedure, treatment of methyl 3-((4-fluorophenyl)amino)-2-methyl-3-oxopropanoate (**1d**, 45 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4d** as white solid (61 mg, 92%). R_f (EtOAc/hexane 3:7) = 0.45. **Mp** 116-118 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 171.7 (C), 167.0 (C), 159.7 (d, *J* = 242.7 Hz, C), 147.1 (C), 133.5 (C), 128.9 (CH), 128.9 (CH), 126.0 (CH), 122.1 (CH), 122.1 (CH), 121.9 (d, *J* = 7.8 Hz, CH), 121.9 (d, *J* = 7.8 Hz, CH), 115.8 (d, *J* = 22.4 Hz, CH), 115.8 (d, *J* = 22.4 Hz, CH), 76.7 (C), 53.4 (CH₃), 18.0 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 8.98 (s, 1H), 7.55-7.51 (m, 2H), 7.33-7.20 (m, 5H), 7.17 (t, *J* = 7.2 Hz, 1H), 7.04 (t, *J* = 8.8 Hz, 2H), 3.84 (s, 3H), 1.61 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 27.4$ min, $\tau_{\text{major}} = 30.9$ min, 79% ee). **HRMS** for C₁₇H₁₇FN₂NaO₄⁺: calcd. [M+Na]⁺: 355.1065, found: 355.1063.

(S)-Methyl 3-((4-acetylphenyl)amino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxopropanoate (4e)




Following the general procedure, treatment of methyl 3-((4-acetylphenyl)amino)-2-methyl-3-oxopropanoate (**1e**, 50 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4e** as white white solid (53 mg, 75%). R_f (EtOAc/hexane 3:7) = 0.39. **Mp** 130-132 °C. **^{13}C NMR** (100 MHz, δ ppm/CDCl₃): 197.4 (C), 171.1 (C), 167.4 (C), 147.1 (C), 141.9 (C), 133.2 (C), 129.9 (CH), 129.9 (CH), 128.9 (CH), 128.9 (CH), 126.2 (CH), 122.4 (CH), 122.4 (CH), 119.3 (CH), 119.3 (CH), 77.1 (C), 53.4 (CH₃), 26.5 (CH₃), 17.7 (CH₃). **1H NMR** (400 MHz, δ ppm/CDCl₃): 9.27 (s, 1H), 7.88 (d, J = 8.0 Hz, 2H), 7.62 (d, J = 8.4 Hz, 3H), 7.28-7.18 (m, 4H), 7.13 (t, J = 7.0 Hz, 1H), 3.77 (s, 3H), 2.52 (s, 3H), 1.57 (s, 3H). Enantiomeric excess was determined by HPLC on Chiraldak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 19.0$ min, $\tau_{\text{major}} = 21.1$ min, 75% ee). **HRMS** for $C_{19}H_{20}N_2NaO_5^+$: calcd. [M+Na]⁺: 379.1264, found: 379.1288.

(S)-Methyl 2-(hydroxy(phenyl)amino)-2-methyl-3-((4-nitrophenyl)amino)-3-oxopropanoate (4f)




Following the general procedure, treatment of methyl 2-methyl-3-((4-nitrophenyl)amino)-3-oxopropanoate (**1f**, 51 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4f** as a yellow solid (68 mg, 95%). R_f (EtOAc/hexane 3:7) = 0.33. **Mp** 161-163 °C. **^{13}C NMR** (100 MHz, δ ppm/CDCl₃): 170.8 (C), 167.7 (C), 146.7 (C), 144.0 (C), 143.3 (C), 129.1 (CH), 129.1 (CH), 126.6 (CH), 125.3 (CH), 125.3 (CH), 122.5 (CH), 122.5 (CH), 119.6 (CH), 119.6 (CH), 76.8 (C), 53.6 (CH₃), 18.4 (CH₃). **1H NMR** (400 MHz, δ ppm CDCl₃): 9.39 (s, 1H), 8.23 (d, J = 9.2 Hz, 2H), 7.77 (d, J = 8.8 Hz, 2H), 7.35-7.26 (m, 3H), 7.22 (d, J = 8.4 Hz, 3H), 3.85 (s, 3H), 1.62 (s, 3H). Enantiomeric excess was determined by HPLC on Chiraldak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 10.3$ min, $\tau_{\text{major}} = 11.5$ min, 85% ee). **HRMS** for $C_{17}H_{17}N_3NaO_6^+$: calcd. [M+Na]⁺: 382.1010, found: 382.1002.

(S)-Methyl 3-((3-bromophenyl)amino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxopropanoate (4g)




Following the general procedure, treatment of methyl 3-((3-bromophenyl)amino)-2-methyl-3-oxopropanoate (**1g**, 57 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4g** as white solid (74 mg, 95%). R_f (EtOAc/hexane 3:7) = 0.26. **Mp** 145-147 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 171.5 (C), 167.1 (C), 147.0 (C), 138.7 (C), 130.5 (CH), 129.0 (CH), 129.0 (CH), 127.8 (CH), 126.1 (CH), 123.0 (CH), 122.8 (C), 122.2 (CH), 122.2 (CH), 118.5 (CH), 76.8 (C), 53.5 (CH₃), 18.0 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 9.05 (s, 1H), 7.86 (s, 1H), 7.47 (d, *J* = 7.6 Hz, 1H), 7.33-7.28 (m, 3H), 7.22-7.16 (m, 5H), 3.83 (s, 3H), 1.60 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 24.8$ min, $\tau_{\text{major}} = 27.6$ min, 63% ee). **HRMS** for C₁₇H₁₇BrN₂NaO₄⁺: calcd. [M+Na]⁺: 415.0264, found: 415.0252, [M+2+Na]⁺: 417.0229.

(S)-Methyl 2-(hydroxy(phenyl)amino)-3-((3-methoxyphenyl)amino)-2-methyl-3-oxopropanoate (4h)




Following the general procedure, treatment of methyl 3-((3-methoxyphenyl)amino)-2-methyl-3-oxopropanoate (**1h**, 47 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4h** as a red solid (52 mg, 75%). R_f (EtOAc/hexane 3:7) = 0.30. **Mp** 135-137 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 171.7 (C), 166.8 (C), 160.4 (C), 147.1 (C), 138.7 (C), 129.8 (CH), 128.9 (CH), 126.0 (CH), 122.1 (CH), 122.1 (CH), 112.1 (CH), 111.0 (CH), 111.0 (CH), 105.5 (CH), 77.2 (C), 55.5 (CH₃), 53.5 (CH₃), 17.9 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 9.01 (s, 1H), 7.36-7.16 (m, 8H), 7.03 (d, *J* = 7.6 Hz, 1H), 6.70 (d, *J* = 7.6 Hz, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 1.61 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 35.3$ min, $\tau_{\text{major}} = 37.5$ min, 80% ee). **HRMS** for C₁₈H₂₀N₂NaO₅⁺: calcd. [M+Na]⁺: 367.1264, found: 367.1269.

(S)-Methyl 2-(hydroxy(phenyl)amino)-2-methyl-3-((3-nitrophenyl)amino)-3-oxopropanoate (4i)




Following the general procedure, treatment of methyl 2-methyl-3-((3-nitrophenyl)amino)-3-oxopropanoate (**1i**, 51 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4i** as a yellow solid (68 mg, 95%). **R_f** (EtOAc/hexane 3:7) = 0.33. **Mp** 155-157 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 171.3 (C), 167.7 (C), 148.8 (C), 146.8 (C), 138.6 (C), 130.0 (CH), 129.0 (CH), 129.0 (CH), 126.4 (CH), 125.7 (CH), 122.5 (CH), 122.5 (CH), 119.3 (CH), 114.9 (CH), 76.8 (C), 53.6 (CH₃), 18.4 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 9.30 (s, 1H), 8.48 (s, 1H), 7.97 (t, *J* = 8.8 Hz, 2H), 7.51 (t, *J* = 8.0 Hz, 1H), 7.43 (s, 1H), 7.33-7.17 (m, 5H), 3.84 (s, 3H), 1.62 (s, 3H). Enantiomeric excess was determined by HPLC on Chiraldak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, τ_{minor} = 19.6 min, τ_{major} = 20.3 min, 41% ee). **HRMS** for C₁₇H₁₇N₃NaO₆⁺: calcd. [M+Na]⁺: 382.1010, found: 382.1032.

(S)-Methyl 3-((2-bromophenyl)amino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxopropanoate (4j)




Following the general procedure, treatment of methyl 3-((2-bromophenyl)amino)-2-methyl-3-oxopropanoate (**1j**, 57 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4j** as white solid (71 mg, 90%). **R_f** (EtOAc/hexane 3:7) = 0.34. **Mp** 125-127 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 171.1 (C), 167.1 (C), 147.1 (C), 135.6 (C), 132.5 (CH), 128.9 (CH), 128.9 (CH), 128.5 (CH), 126.3 (CH), 125.6 (CH), 122.8 (CH), 122.8 (CH), 122.0 (CH), 114.0 (C), 76.8 (C), 53.4 (CH₃), 18.0 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 9.67 (s, 1H), 8.32 (d, *J* = 8 Hz, 1H), 7.57 (d, *J* = 8 Hz, 1H), 7.33-7.18 (m, 6H), 7.10 (s, 1H), 7.01 (t, *J* = 7.2 Hz, 1H), 3.84 (s, 3H), 1.63 (s, 3H). Enantiomeric excess was determined by HPLC on Chiraldak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, τ_{minor} = 14.0 min, τ_{major} = 15.1 min, 54% ee). **HRMS** for C₁₇H₁₇BrN₂NaO₄⁺: calcd. [M+Na]⁺: 415.0264, found: 415.0242, [M+2+Na]⁺: 417.0226.

(S)-Methyl 3-((2,5-dimethylphenyl)amino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxo-propanoate (1C less) (4k)




Following the general procedure, treatment of methyl 3-((2,5-dimethylphenyl)amino)-2-methyl-3-oxopropanoate (**1k**, 47 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4k** as white solid (65 mg, 95%). **R**_f (EtOAc/hexane 3:7) = 0.50. **Mp** 123-125 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 171.9 (C), 166.7 (C), 147.3 (C), 136.6 (C), 135.2 (C), 130.3 (CH), 128.8 (CH), 128.8 (CH), 125.9 (CH), 125.6 (CH), 122.7 (CH), 121.8 (CH), 121.8 (CH), 76.6 (C), 53.3 (CH₃), 21.2 (CH₃), 17.9 (CH₃), 17.1 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 9.01 (s, 1H), 7.77 (s, 1H), 7.51 (s, 1H), 7.32-7.22 (m, 4H), 7.15 (t, *J* = 7.2 Hz, 1H), 7.08 (d, *J* = 7.6 Hz, 1H), 6.90 (d, *J* = 7.6 Hz, 1H), 3.82 (s, 3H), 2.32 (s, 3H), 2.23 (s, 3H), 1.66 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 95:5 V/V, flow rate 1.0 mL/min, 254 nm, τ_{minor} = 26.6 min, τ_{major} = 27.9 min, 85% ee). **HRMS** for C₁₉H₂₂N₂NaO₄⁺: calcd. [M+Na]⁺: 365.1472, found: 365.1445.

(S)-Methyl 3-((3,4-dimethoxyphenyl)amino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxo-propanoate (4l)




Following the general procedure, treatment of methyl 3-((3,4-dimethoxyphenyl)amino)-2-methyl-3-oxopropanoate (**1l**, 50 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 4 h followed by column chromatography afforded the product **4l** as white solid (61 mg, 82%). **R**_f (EtOAc/hexane 3:7) = 0.16. **Mp** 143-145 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 171.8 (C), 166.6 (C), 149.3 (C), 147.2 (C), 146.2 (C), 131.2 (C), 128.9 (CH), 128.9 (CH), 125.9 (CH), 122.1 (CH), 122.1 (CH), 111.8 (CH), 111.5 (CH), 104.7 (CH), 76.7 (C), 56.3 (CH₃), 56.1 (CH₃), 53.4 (CH₃), 17.9 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 8.93 (s, 1H), 7.40-7.28 (m, 4H), 7.23-7.21 (m, 2H), 7.15 (t, *J* = 7.2 Hz, 1H), 6.94 (dd, *J* = 8.8 Hz, 2.4 Hz, 1H), 6.82 (d, *J* = 8.8 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 3.83 (s, 3H), 1.61 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, τ_{minor} = 16.3 min, τ_{major} = 17.5 min, 91% ee). **HRMS** for C₁₉H₂₃N₂O₆⁺: calcd. [M+H]⁺: 375.1551, found: 375.1554.

(S)-Methyl 2-(hydroxy(phenyl)amino)-2-methyl-3-((4-methylthiazol-2-yl)amino)-3-oxo-propanoate (4m)




Following the general procedure, treatment of methyl 2-methyl-3-((4-methylthiazol-2-yl)amino)-3-oxopropanoate (**1m**, 45 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4m** as white solid (44 mg, 66%). **R**_f (EtOAc/hexane 3:7) = 0.50. **Mp** 133-135 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 170.2 (C), 167.2 (C), 157.3 (C), 147.4 (C), 147.4 (C), 128.8 (CH), 128.8 (CH), 126.3 (CH), 122.9 (CH), 122.9 (CH), 108.7 (CH), 76.8 (C), 53.4 (CH₃), 17.5 (CH₃), 17.0 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 7.26-7.20 (m, 3H), 7.16-7.15 (m, 2H), 7.10 (t, *J* = 5.8 Hz, 1H), 6.50 (s, 1H), 3.70 (s, 3H), 2.30 (s, 3H), 1.57 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, τ_{minor} = 9.1 min, τ_{major} = 9.8 min, 62% ee). **HRMS** for C₁₅H₁₈N₃O₄S⁺: calcd. [M+H]⁺: 336.1013, found: 336.1010.

(S)-Methyl 3-(*tert*-butylamino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxopropanoate (4n)




Following the general procedure, treatment of methyl 3-(*tert*-butylamino)-2-methyl-3-oxopropanoate (**1n**, 34 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4n** as white solid (50 mg, 85%). **R**_f (EtOAc/hexane 3:7) = 0.50. **Mp** 144-146 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 172.4 (C), 167.9 (C), 147.5 (C), 128.6 (CH), 128.6 (CH), 125.0 (CH), 121.3 (CH), 121.3 (CH), 76.1 (C), 53.1 (CH₃), 51.5 (C), 28.5 (CH₃), 28.5 (CH₃), 28.5 (CH₃), 18.2 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 7.42 (s, 1H), 7.30-7.26 (m, 2H), 7.18-7.16 (m, 2H), 7.11 (t, *J* = 7.2 Hz, 1H), 6.98 (s, 1H), 3.80 (s, 3H), 1.56 (s, 3H), 1.36 (s, 9H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, τ_{minor} = 13.6 min, τ_{major} = 14.5 min, 71% ee). **HRMS** for C₁₅H₂₃N₂O₄⁺: calcd. [M+H]⁺: 295.1652, found: 295.1653.

(S)-Ethyl 3-((4-bromophenyl)amino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxopropanoate (4o)




Following the general procedure, treatment of ethyl 3-((4-bromophenyl)amino)-2-methyl-3-oxopropanoate (**1o**, 60 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4o** as white solid (54 mg, 66%). R_f (EtOAc/hexane 3:7) = 0.22. **Mp** 122-124 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 171.0 (C), 167.0 (C), 147.2 (C), 136.5 (C), 132.1 (CH), 132.1 (CH), 128.8 (CH), 128.8 (CH), 126.0 (CH), 122.1 (CH), 122.1 (CH), 121.6 (CH), 121.6 (CH), 117.3 (C), 76.8 (C), 62.8 (CH₂), 17.6 (CH₃), 14.0 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 9.02 (s, 1H), 7.50-7.44 (m, 4H), 7.32-7.26 (m, 2H), 7.22-7.16 (m, 3H), 4.31 (q, *J* = 7.2 Hz, 2H), 1.60 (s, 3H), 1.29 (t, *J* = 7.2 Hz, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 95:5 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 10.6$ min, $\tau_{\text{major}} = 13.2$ min, 76% ee). **HRMS** for C₁₈H₁₉BrN₂NaO₄⁺: calcd. [M+Na]⁺: 429.0420, found: 429.0476, [M+2+Na]⁺: 431.0422.

(S)-Ethyl 3-((3,4-dimethoxyphenyl)amino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxopropanoate (4p)




Following the general procedure, treatment of ethyl 3-((3,4-dimethoxyphenyl)amino)-2-methyl-3-oxopropanoate (**1p**, 56 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4p** as white solid (51 mg, 66%). R_f (EtOAc/hexane 3:7) = 0.22. **Mp** 132-134 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 171.3 (C), 166.7 (C), 149.2 (C), 147.3 (C), 146.2 (C), 131.2 (C), 128.8 (CH), 128.8 (CH), 125.8 (CH), 122.0 (CH), 122.0 (CH), 111.8 (CH) 111.5 (CH), 104.7 (CH), 76.6 (C), 62.8 (CH₂), 56.2 (CH₃), 56.0 (CH₃), 17.7 (CH₃), 14.0 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 8.91 (s, 1H), 7.39 (d, *J* = 2.0 Hz, 1H), 7.34-7.29 (m, 3H), 7.24-7.22 (m, 2H), 7.16 (t, *J* = 5.8 Hz, 1H), 6.96 (dd, *J* = 6.8, 2.0 Hz, 1H), 6.83 (d, *J* = 6.8 Hz, 1H), 4.32-4.30 (m, 2H), 3.90 (s, 3H), 3.87 (s, 3H), 1.62 (s, 3H), 1.30 (t, *J* = 5.8 Hz, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 36.3$ min, $\tau_{\text{major}} = 40.1$ min, 80% ee). **HRMS** for C₂₀H₂₄N₂NaO₆⁺: calcd. [M+Na]⁺: 411.1527, found: 411.1540.

(S)-Ethyl 2-(hydroxy(phenyl)amino)-2-methyl-3-((4-nitrophenyl)amino)-3-oxopropanoate (4q)




Following the general procedure, treatment of ethyl 2-methyl-3-((4-nitrophenyl)amino)-3-oxopropanoate (**1q**, 53 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4q** as white solid (52 mg, 70%). **R_f** (EtOAc/hexane 3:7) = 0.22. **Mp** 115-117 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 170.7 (C), 167.8 (C), 146.9 (C), 143.9 (C), 143.3 (C), 129.0 (CH), 129.0 (CH), 126.4 (CH), 125.2 (CH), 125.2 (CH), 122.5 (CH), 122.5 (CH), 119.5 (CH) 119.5 (CH), 76.8 (C), 63.0 (CH₂), 18.0 (CH₃), 14.0 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 9.42 (s, 1H), 8.20 (d, *J* = 8.8 Hz, 2H), 7.74 (d, *J* = 8.8 Hz, 2H), 7.60 (s, 1H), 7.32-7.26 (m, 2H), 7.22-7.16 (m, 3H), 4.29 (q, *J* = 7.0 Hz, 2H), 1.60 (s, 3H), 1.28 (t, *J* = 7.2 Hz, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, τ_{minor} = 12.8 min, τ_{major} = 24.8 min, 67% ee). **HRMS** for C₁₈H₁₉N₃NaO₆⁺: calcd. [M+Na]⁺: 396.1166, found: 396.1168.

(S)-*tert*-Butyl 3-((3,4-dimethoxyphenyl)amino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxopropanoate (4r)




Following the general procedure, treatment of *t*-butyl 3-((3,4-dimethoxyphenyl)amino)-2-methyl-3-oxopropanoate (**1r**, 62 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 6 h followed by column chromatography afforded the product **4r** as a red solid (42 mg, 50%). **R_f** (EtOAc/hexane 3:7) = 0.28. **Mp** 96-98 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 170.6 (C), 167.2 (C), 149.3 (C), 147.5 (C), 146.2 (C), 131.3 (C), 128.8 (CH), 128.8 (CH), 125.7 (CH), 122.2 (CH), 122.2 (CH), 112.0 (CH), 111.6 (CH), 104.9 (CH), 84.5 (C), 77.2 (C), 56.3 (CH₃), 56.1 (CH₃), 28.0 (CH₃), 28.0 (CH₃), 28.0 (CH₃), 18.3 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 8.90 (s, 1H), 7.54 (s, 1H), 7.36-7.26 (m, 5H), 7.15 (t, *J* = 7.2 Hz, 1H), 6.96 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.82 (d, *J* = 8.4 Hz, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 1.56 (s, 3H), 1.50 (s, 9H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, τ_{minor} = 24.0 min, τ_{major} = 24.9 min, 84% ee). **HRMS** for C₂₂H₂₉N₂O₆: calcd. [M+H]⁺: 417.2020, found: 417.2018

(S)-*tert*-Butyl 2-(hydroxy(phenyl)amino)-2-methyl-3-((4-nitrophenyl)amino)-3-oxopropanoate (4s)




Following the general procedure, treatment of *tert*-butyl 2-methyl-3-((4-nitrophenyl)amino)-3-oxopropanoate (**1s**, 59 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4s** as a yellow solid (48 mg, 60%). R_f (EtOAc/hexane 3:7) = 0.23. **Mp** 115-117 °C. **13C NMR** (100 MHz, δ ppm/CDCl₃): 170.0 (C), 168.3 (C), 146.9 (C), 143.9 (C), 143.4 (C), 128.9 (CH), 128.9 (CH), 126.4 (CH), 125.2 (CH), 125.2 (CH), 122.6 (CH), 122.6 (CH), 119.5 (CH), 119.5 (CH), 85.0 (C), 77.2 (C), 28.0 (CH₃), 28.0 (CH₃), 28.0 (CH₃), 18.8 (CH₃). **1H NMR** (400 MHz, δ ppm/CDCl₃): 9.36 (s, 1H), 8.24 (d, J = 8.8 Hz, 2H), 7.76 (d, J = 9.2 Hz, 2H), 7.73 (s, 1H), 7.32 (t, J = 7.8 Hz, 2H), 7.25-7.18 (m, 3H), 1.56 (s, 3H), 1.50 (s, 9H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 95:5 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 11.3$ min, $\tau_{\text{major}} = 12.5$ min, 82% ee). **HRMS** for C₂₀H₂₃N₃NaO₆: calcd. [M+Na]⁺: 424.1479, found: 424.1486.

(S)-4-Methoxybenzyl 3-((4-bromophenyl)amino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxopropanoate (4t)




Following the general procedure, treatment of 4-methoxybenzyl 3-((4-bromophenyl)amino)-2-methyl-3-oxopropanoate (**1t**, 78 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4t** as white solid (75 mg, 75%). R_f (EtOAc/hexane 3:7) = 0.22. **Mp** 145-147 °C. **13C NMR** (100 MHz, δ ppm/CDCl₃): 170.6 (C), 166.7 (C), 160.0 (C), 147.1 (C), 136.5 (C), 132.1 (CH), 132.1 (CH), 130.3 (CH), 130.3 (CH), 128.9 (CH), 128.9 (CH), 126.8 (C), 125.9 (CH), 122.0 (CH), 122.0 (CH), 121.6 (CH), 121.6 (CH), 117.3 (C), 114.1 (CH), 114.1 (CH), 77.0 (C), 68.2 (CH₂), 55.4 (CH₃), 17.4 (CH₃). **1H NMR** (400 MHz, δ ppm/CDCl₃): 8.94 (s, 1H), 7.44-7.37 (m, 4H), 7.26-7.22 (m, 5H), 7.14-7.13 (m, 3H), 6.82 (d, J = 8.4 Hz, 2H), 5.23-5.16 (m, 2H), 3.79 (s, 3H), 1.58 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 95:5 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 7.5$ min, $\tau_{\text{major}} = 8.2$ min, 82% ee). **HRMS** for C₂₄H₂₃BrN₂NaO₅⁺: calcd. [M+Na]⁺: 521.0683, found: 521.0705, [M+2+Na]⁺: 415.0264.

(S)-4-Methoxybenzyl 2-(hydroxy(phenyl)amino)-3-((4-methoxyphenyl)amino)-2-methyl-3-oxopropanoate (4u)




Following the general procedure, treatment of 4-methoxybenzyl 3-((4-methoxyphenyl)amino)-2-methyl-3-oxopropanoate (**1u**, 69 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4u** as white solid (63 mg, 70%). R_f (EtOAc/hexane 3:7) = 0.22. **Mp** 155-157 °C. **13C NMR** (100 MHz, δ ppm/CDCl₃): 170.7 (C), 166.3 (C), 159.9 (C), 156.6 (C), 147.3 (C), 130.5 (C), 130.2 (CH), 130.2 (CH), 128.7 (CH), 128.7 (CH), 126.9 (C), 125.5 (CH), 121.7 (CH), 121.7 (CH), 121.7 (CH), 121.7 (CH), 114.2 (CH), 114.2 (CH) 114.0 (CH), 114.0 (CH), 76.8 (C), 68.0 (CH₂), 55.5 (CH₃), 55.3 (CH₃) 17.2 (CH₃). **1H NMR** (400 MHz, δ ppm/CDCl₃): 8.85 (s, 1H), 7.47-7.42 (m, 2H), 7.26-7.14 (m, 8H), 6.89-6.85 (m, 4H), 5.27-5.20 (m, 2H), 3.82 (s, 6H), 1.63 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 15.6$ min, $\tau_{\text{major}} = 16.9$ min, 81% ee). **HRMS** for C₂₅H₂₇N₂O₆⁺: calcd. [M+H]⁺: 451.1864, found: 451.1855.

(S)-3-Methoxybenzyl 3-((4-bromophenyl)amino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxopropanoate (4v)




Following the general procedure, treatment of 3-methoxybenzyl 3-((4-bromophenyl)amino)-2-methyl-3-oxopropanoate (**1v**, 78 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4v** as white solid (77 mg, 77%). R_f (EtOAc/hexane 3:7) = 0.22. **Mp** 135-137 °C. **13C NMR** (100 MHz, δ ppm/CDCl₃): 170.6 (C), 166.8 (C), 159.9 (C), 147.1 (C), 136.5 (C), 136.3 (C), 132.1 (CH), 132.1 (CH), 129.9 (CH), 128.9 (CH), 128.9 (CH), 126.0 (CH), 122.1 (CH), 122.1 (CH), 121.7 (CH), 121.7 (CH), 120.4 (CH), 117.4 (C), 114.3 (CH), 113.6 (CH), 77.0 (C), 68.1 (CH₂), 55.3 (CH₃), 17.5 (CH₃). **1H NMR** (400 MHz, δ ppm/CDCl₃): 9.00 (s, 1H), 7.44-7.39 (m, 4H), 7.30 (s, 1H), 7.25-7.22 (m, 3H), 7.16-7.13 (m, 3H), 6.87-6.82 (m, 3H), 5.20 (d, *J* = 2.4 Hz, 2H), 3.73 (s, 3H), 1.61 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IA column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 235 nm), minor enantiomer $t_r = 15.9$ min, major enantiomer $t_r = 13.8$ min, 83% ee. **HRMS** for C₂₄H₂₄BrN₂O₅⁺: calcd. [M+H]⁺: 499.0863, found: 499.0873, [M+2+H]⁺: 501.0848.

(S)-3,4,5-Trimethoxybenzyl 3-((4-bromophenyl)amino)-2-(hydroxy(phenyl)amino)-2-methyl-3-oxopropanoate (4w)




Following the general procedure, treatment of 3,4,5-trimethoxybenzyl 3-((4-bromophenyl)amino)-2-methyl-3-oxopropanoate (**1w**, 90.0 mg, 0.20 mmol) with nitrosobenzene (**2a**, 26 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4w** as white solid (73 mg, 65%). R_f (EtOAc/hexane 3:7) = 0.10. **Mp** 140-142 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 170.4 (C), 166.9 (C), 153.3 (C), 153.3 (C), 153.3 (C), 147.1 (C), 138.1 (C), 136.5 (C), 132.1 (CH), 132.1 (CH), 132.1 (CH), 130.4 (C), 128.8 (CH), 125.9 (CH), 122.1 (CH), 121.5 (CH), 121.5 (CH), 117.3 (CH), 105.2 (CH), 105.2 (CH), 77.2 (C), 68.2 (CH₂), 60.9 (CH₃), 56.1 (CH₃), 56.1 (CH₃), 17.7 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 9.05 (s, 1H), 7.42 (s, 4H), 7.24-7.20 (m, 2H), 7.16-7.14 (m, 3H), 6.49 (s, 2H), 5.17 (s, 2H), 3.81 (s, 3H), 3.75 (s, 6H), 1.62 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IA column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 235 nm), minor enantiomer t_r = 19.4 min, major enantiomer t_r = 16.8 min, 39% ee. **HRMS** for C₂₆H₂₈BrN₂O₇⁺: calcd. [M+Na]⁺: 581.0894, found: 581.0901, [M+2+Na]⁺: 583.0881.

(S)-Methyl 3-((4-bromophenyl)amino)-2-(hydroxy(o-tolyl)amino)-2-methyl-3-oxopropanoate (4x)




Following the general procedure, treatment of methyl 3-((4-bromophenyl)amino)-2-methyl-3-oxopropanoate (**1a**, 57 mg, 0.20 mmol) with 2-methylnitrosobenzene (**2b**, 29 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 3 h followed by column chromatography afforded the product **4x** as white solid (25 mg, 31%). R_f (EtOAc/hexane 3:7) = 0.50. **Mp** 145-147 °C. **¹³C NMR** (100 MHz, δ ppm/CDCl₃): 173.2 (C), 168.7 (C), 144.2 (C), 136.7 (C), 132.2 (CH), 132.2 (CH), 131.6 (C), 128.1 (CH), 127.0 (CH), 123.0 (CH), 123.0 (C), 121.7 (CH), 121.7 (CH), 117.3 (CH), 74.7 (C), 53.4 (CH₃), 20.9 (CH₃), 18.8 (CH₃). **¹H NMR** (400 MHz, δ ppm/CDCl₃): 9.22 (s, 1H), 7.81 (s, 1H), 7.54-7.39 (m, 4H), 7.26-7.16 (m, 4H), 3.93 (s, 3H), 2.49 (s, 3H), 1.51 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 95:5 V/V, flow rate 1.0 mL/min, 254 nm, t_{minor} = 6.6 min, t_{major} = 8.4 min, 30% ee). **HRMS** for C₁₈H₁₉BrN₂NaO₄: calcd. [M+Na]⁺: 429.0420, found: 429.0410, [M+2+Na]⁺: 431.0264.

(S)-Methyl 3-((3,4-dimethoxyphenyl)amino)-2-(hydroxy(*o*-tolyl)amino)-2-methyl-3-oxopropanoate (4y)



Following the general procedure, treatment of methyl 3-((3,4-dimethoxyphenyl)amino)-2-methyl-3-oxopropanoate (**1I**, 57 mg, 0.20 mmol) with 2-methylnitrosobenzene (**2b**, 29 mg, 0.24 mmol) in the presence of (*R,R*)-TUC (**3a**, 17 mg, 0.04 mmol) in toluene (3 mL) at 0 °C for 4 h followed by column chromatography afforded the product **4y** (27 mg, 35%). R_f (EtOAc/hexane 3:7) = 0.42. **Mp** 129-131 °C. **13C NMR** (100 MHz, δ ppm/CDCl₃): 173.4 (C), 168.4 (C), 149.4 (C), 146.2 (C), 144.4 (C), 136.8 (C), 131.5 (CH), 131.4 (C), 127.9 (CH), 127.0 (CH), 123.0 (CH), 111.9 (CH), 111.6 (CH), 104.9 (CH), 74.7 (C), 56.3 (CH₃), 56.1 (CH₃), 53.3 (CH₃), 21.0 (CH₃), 18.8 (CH₃). **1H NMR** (400 MHz, δ ppm/CDCl₃): 9.12 (s, 1H), 7.84 (s, 1H), 7.49 (s, 1H), 7.26-7.18 (m, 4H), 6.91-6.83 (m, 2H), 3.94 (s, 3H), 3.91 (s, 3H), 3.87 (s, 3H), 2.50 (s, 3H), 1.52 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IC column (Hexane/Ethanol 90:10 V/V, flow rate 1.0 mL/min, 254 nm, $\tau_{\text{minor}} = 16.5$ min, $\tau_{\text{major}} = 23.0$ min, 30% ee). **HRMS** for C₂₀H₂₄N₂NaO₆⁺: calcd. [M+H]⁺: 411.1527, found: 411.1527.

Synthesis of methyl-3-((4-bromophenyl)amino)-2-methyl-3-oxo-2-(phenylamino)propanoate (5)



To a 10 mL round-bottomed flask charged with **4a** (78 mg, 0.20 mmol, 1 equiv) were added Zn dust (260 mg, 4.0 mmol, 20 equiv) and acetic acid (2 mL). This reaction mixture was stirred at 25 °C for 2 h. After the completion of the reaction, as indicated by TLC, the reaction was quenched with water and extracted with ethyl acetate. The combined organic layer was washed with saturated solution of NaHCO₃ and brine. After drying over anhydrous Na₂SO₄ the solvent was evaporated under reduced pressure. The residue was purified by column chromatography (100–200 mesh silica gel) using ethyl acetate/hexane as the eluent to afford compound **5** as white solid (70 mg, 93%). R_f (ethyl acetate/hexane 15:85) = 0.35. **Mp** 183-185 °C. **13C NMR** (100 MHz, δ ppm/CDCl₃): 172.1 (C), 167.6 (C), 142.9 (C), 136.5 (C), 132.1 (CH), 132.1 (CH), 129.6 (CH), 129.6 (CH), 121.5 (CH), 121.5 (CH), 120.5 (CH), 117.4 (C), 116.6 (CH), 116.6 (CH), 66.0 (C), 54.1 (CH₃), 18.9 (CH₃). **1H NMR** (400 MHz, δ ppm/CDCl₃): 8.90 (s, 1H), 7.42 (s, 4H), 7.20 (t, J = 8.0 Hz, 2H), 6.90 (t, J = 7.2 Hz, 1H), 6.65 (d, J = 7.6 Hz,

2H), 5.12 (s, 1H), 3.85 (s, 3H), 1.76 (s, 3H). Enantiomeric excess was determined by HPLC on Chiralpak IA column (Hexane/Ethanol 92:8 V/V, flow rate 1.0 mL/min, 251 nm, $\tau_{\text{minor}} = 24.9$ min, $\tau_{\text{major}} = 15.9$ min, 49% ee). **HRMS** for $\text{C}_{17}\text{H}_{18}\text{BrN}_2\text{O}_3^+$: calcd. $[\text{M}+\text{H}]^+$: 377.0495, found: 377.0498, $[\text{M}+2+\text{H}]^+$: 379.0477.

X-ray data of compound 4a

X-ray data collection and structure refinement details of compound 4a

A good quality colorless single crystal of size $0.28 \times 0.22 \times 0.19$ mm, was selected under a polarizing microscope and mounted on a glass fiber for data collection. Single crystal X-ray data for compound **4a** were collected on a Rigaku Kappa 3 circle diffractometer equipped with the AFC12 goniometer and enhanced sensitivity (HG) Saturn724+ CCD detector in the 4×4 bin mode using the monochromated $\text{MoK}\alpha$ radiation generated from the microfocus sealed tube MicroMax-003 X-ray generator equipped with specially designed confocal multilayer optics. Data collection was performed using ω -scans of 0.5° steps at 293(2) K. Cell determination, data collection, and data reduction was performed using the Rigaku CrystalClear-SM Expert 2.1 b24² software. Structure solution and refinement were performed by using SHELXTL-NT.³ Refinement of coordinates and anisotropic thermal parameters of non-hydrogen atoms were carried out by the full-matrix least-squares method. The hydrogen atoms attached to carbon atoms were generated with idealized geometries and isotropically refined using a riding model.




Figure S1: ORTEP diagram drawn with 30% ellipsoid probability for non-H atoms of the crystal structure of chiral compound **4a** determined at 293 K. The absolute configuration of C7 is S.


Table S1: Crystal data and structure refinement details for compound **4a**.


Compound	4a
Empirical formula	C ₁₇ H ₁₇ Br N ₂ O ₄
Formula weight	393.24
Crystal System	Orthorhombic
Space group	<i>P</i> 2 ₁ 2 ₁ 2 ₁
<i>a</i> (Å)	10.151(3)
<i>b</i> (Å)	12.755(3)
<i>c</i> (Å)	14.560(4)
α (°)	90.00
β (°)	90.00
γ (°)	90.00
<i>V</i> (Å ³)	1885.2(9)
<i>Z</i>	4
D _c (g/cm ³)	1.386
<i>F</i> ₀₀₀	800
μ (mm ⁻¹)	2.201
θ _{max} (°)	25.36
Total reflections	12849
Unique reflections	3413
Reflections [<i>I</i> > 2σ(<i>I</i>)]	1773
Parameters	217
<i>R</i> _{int}	0.0488
Goodness-of-fit	0.959
<i>R</i> [<i>F</i> ² > 2σ(<i>F</i> ²)]	0.0488
<i>wR</i> (<i>F</i> ² , all data)	0.1242
CCDC No.	1898632



References


1. R. A. Dhokale, P. R. Thakare, S. B. Mhaske, *Org. Lett.* **2012**, *14*, 3994.
2. CrystalClear 2.1, Rigaku Corporation, Tokyo, Japan.
3. G. M. Sheldrick, *Acta Crystallogr., Sect. A* 2008, **64**, 112.


Copies of ^1H and ^{13}C NMR spectra for all compounds




















































































HPLC chromatograms of all compounds





Area % Height %



Sr. No.	Component Name	Ret. Time.	Area μ volt sec	Height μ volt	Area %	Height %	ID	
1		12.96	33221.54	1217	54.82	53.65	U	M
2		13.87	27374.23	1051	45.18	46.35	U	M
			60595.77	2268	100.00	100.00		




Area % Height %

Sr. No.	Component Name	Ret. Time.	Area μ volt sec	Height μ volt	Area %	Height %	ID	
1		12.99	3523.49	154	3.51	5.00	U	M
2		13.89	96969.54	2931	96.49	95.00	U	M
			100493.03	3085	100.00	100.00		









Peak Results

	Name	RT	Area	Height	% Area
1		28.321	10707784	133335	51.62
2		32.564	10036241	93421	48.38




Peak Results

	Name	RT	Area	Height	% Area
1		27.425	8325398	98863	10.37
2		30.908	71947422	608787	89.63




Peak Results

Peak Results					
	Name	RT	Area	Height	% Area
1		19.418	56292755	1563268	51.24
2		21.530	53665300	1358806	48.76




Peak Results

Name	RT	Area	Height	% Area
1	19.034	3993166	93706	12.64
2	21.060	27595420	729079	87.36




Area % Height %

Sr. No.	Component Name	Ret. Time.	Area μ volt sec	Height μ volt	Area %	Height %	ID	
1		10.36	39617.03	1217	47.63	50.24	U	M
2		11.60	43557.03	1205	52.37	49.76	U	M
			83174.06	2422	100.00	100.00		




Area % Height %

Sr. No.	Component Name	Ret. Time.	Area μ volt sec	Height μ volt	Area %	Height %	ID	
1		10.26	9392.74	308	6.87	7.80	U	M
2		11.47	127287.94	3645	93.13	92.20	U	M
			136680.69	3954	100.00	100.00		





Peak Results


	Name	RT	Area	Height	% Area
1		25.219	11204993	202204	51.05
2		28.020	10745283	160409	48.95



Peak Results


	Name	RT	Area	Height	% Area
1		24.756	2533821	34327	18.48
2		27.565	11180672	170961	81.52






Peak Results

	Name	RT	Area	Height	% Area
1		19.591	97163026	2485510	48.41
2		20.318	103542518	2438182	51.59




Peak Results

	Name	RT	Area	Height	% Area
1		19.557	37831371	1051532	29.71
2		20.338	89504210	2111206	70.29




Peak Results

	Name	RT	Area	Height	% Area
1		14.006	62680567	2119760	50.00
2		15.058	62668088	1898139	50.00




Peak Results

	Name	RT	Area	Height	% Area
1		14.024	17108258	579956	22.98
2		15.085	57354909	1670757	77.02




Area % Height %

Sr. No.	Component Name	Ret. Time.	Area μ volt sec	Height μ volt	Area %	Height %	ID	
1		26.93	60463.60	1394	51.31	51.80	U	M
2		28.29	57382.23	1297	48.69	48.20	U	M
			117845.83	2691	100.00	100.00		




Area % Height %

Sr. No.	Component Name	Ret. Time.	Area μ volt sec	Height μ volt	Area %	Height %	ID	
1		26.57	17428.91	474	5.45	7.27	U	M
2		27.89	302651.03	6045	94.55	92.73	U	M
			320079.94	6520	100.00	100.00		





Peak Results



	Name	RT	Area	Height	% Area
1		15.799	3752918	110207	42.66
2		17.092	5043732	113771	57.34






Area % Height %

Sr. No.	Component Name	Ret. Time.	Area μ volt sec	Height μ volt	Area %	Height %	ID	
1		16.32	1559.89	0	4.71	0.00	U	M
2		17.54	31578.29	1034	95.29	100.00	U	M
			33138.17	1034	100.00	100.00		












Peak Results



	Name	RT	Area	Height	% Area
1		35.788	27176289	403191	51.10
2		39.869	26007205	339869	48.90







Peak Results



	Name	RT	Area	Height	% Area
1		36.267	2004120	30945	9.95
2		40.078	18135985	236805	90.05













Peak Results


Name	RT	Area	Height	% Area
1	15.633	2248592	56936	9.67
2	16.932	21013727	470780	90.33



Peak RetTime Type Width Area Height Area


#	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	13.787	BB	0.3780	1.27783e4	514.14838	91.3068
2	15.987	BB	0.5348	1216.60291	34.38516	8.6932

Totals : 1.39949e4 548.53354




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.700	BV	0.5911	1.56196e4	396.91266	54.9978
2	19.266	VB	0.6136	1.27808e4	320.27298	45.0022
Totals :						2.84004e4 717.18564

Additional Info : Peak(s) manually integrated




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	16.833	BV	0.5301	2.21835e4	637.23199	69.3520
2	19.423	VV	0.6299	9803.32813	235.38416	30.6480
Totals :						3.19869e4 872.61615





Peak Results


	Name	RT	Area	Height	% Area
1		6.783	12985981	679709	49.50
2		9.103	13249321	630724	50.50



Peak Results

	Name	RT	Area	Height	% Area
1		6.632	15350541	1044740	34.84
2		8.401	28715872	2086879	65.16






1 PDA Multi 1 / 251nm 4nm

PeakTable

Ch1 251nm 4nm

Peak#	Ret. Time	Area	Height	Area %
1	16.036	926140	20401	49.620
2	25.340	940332	9649	50.380
Total		1866472	30050	100.000



1 PDA Multi 1 / 250nm 4nm

PeakTable

Ch1 250nm 4nm

Peak#	Ret. Time	Area	Height	Area %
1	15.920	4998736	98606	74.547
2	24.971	1706783	17375	25.453
Total		6705519	115981	100.000